Guardant Health Launches New Guardant360 TissueNext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer

6/4/24 8:09:21 AM ET

Medical Specialities

Health Care

Get the next $GH alert in real time by email

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes
Operational improvements streamline workflow and shorten time to results
Upgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tumors

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved the test's operational workflow for a faster turnaround time.

Get the next $GH alert in real time by email

Date	Price Target	Rating	Analyst
6/28/2024	$36.00	Neutral → Buy	Guggenheim
6/3/2024	$32.00	Buy	Jefferies
4/24/2024	$28.00	Buy	Craig Hallum
12/14/2023		Neutral	Guggenheim
12/13/2023		Peer Perform	Wolfe Research
11/13/2023	$27.00	Mkt Perform → Outperform	Raymond James
9/28/2023	$34.00	Outperform	Bernstein
9/27/2023	$40.00	Neutral → Overweight	Piper Sandler

Guardant Health Launches New Guardant360 TissueNext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer

Chat with this insight

Recent Analyst Ratings for $GH

$GH Press Releases

Fastest customizable press release news feed in the world

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health to Participate in Upcoming Investor Conferences

$GH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Guardant Health Inc.

SEC Form SC 13G filed by Guardant Health Inc.

Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

$GH Market Insights

Live Market Insights

Guardant Health Launches Enhanced Guardant360 Test On Guardant Infinity Platform; New Test Covers 10 Times More Genes And Quantifies Tumor Burden With 10 Times Higher Sensitivity; Medicare And Major Private Payers Cover Test For Comprehensive Genomic Profiling Of Advanced Solid Tumors

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast

B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $40

$GH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

$GH Financials

Live finance-specific insights

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

$GH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guardant Health upgraded by Guggenheim with a new price target

Jefferies resumed coverage on Guardant Health with a new price target

Craig Hallum resumed coverage on Guardant Health with a new price target

$GH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$GH Leadership Updates

Live Leadership Updates

Chief Information Officer Kalia Kumud sold $204,722 worth of shares (7,000 units at $29.25), decreasing direct ownership by 28% to 17,744 units (SEC Form 4)

Director Tariq Musa converted options into 250 shares, increasing direct ownership by 5% to 4,996 units (SEC Form 4)

Director Potter Myrtle S converted options into 68 shares, increasing direct ownership by 0.50% to 13,653 units (SEC Form 4)

Roberto A. Mignone Joins Guardant Health Board of Directors

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer

$GH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 30, 2024 - FDA Roundup: July 30, 2024

May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

$GH SEC Filings

SEC Form 144 filed by Guardant Health Inc.

SEC Form 10-Q filed by Guardant Health Inc.

Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Recent Analyst Ratings for
$GH

$GH
Press Releases

$GH
Large Ownership Changes

$GH
Market Insights

$GH
Insider Purchases

$GH
Financials

$GH
Analyst Ratings

$GH
Insider Trading

$GH
Leadership Updates

$GH
FDA approvals

$GH
SEC Filings